SABS logo

SABS
SAB Biotherapeutics Inc

1,751
Mkt Cap
$193.61M
Volume
1.12M
52W High
$6.60
52W Low
$1.60
PE Ratio
-1.42
SABS Fundamentals
Price
$3.94
Prev Close
$3.80
Open
$4.38
50D MA
$3.86
Beta
0.63
Avg. Volume
418,570.46
EPS (Annual)
-$0.7944
P/B
1.19
Rev/Employee
$0.00
$138.77
Loading...
Loading...
News
all
press releases
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Average Rating of "Moderate Buy" by Brokerages
SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, five have assigned a buy reco...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
SAB Biotherapeutics (SABS) Expected to Announce Earnings on Friday
SAB Biotherapeutics (NASDAQ:SABS) will be releasing its Q1 2026 earnings before the market opens on Friday, May 8. (View Earnings Report at...
MarketBeat·6d ago
News Placeholder
Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Expands By 19.8%
SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) saw a large increase in short interest in April. As of April 15th, there was short interest totaling 3,000,764 shares, an increase of 19.8...
MarketBeat·7d ago
News Placeholder
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Average Rating of "Moderate Buy" from Analysts
Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight analysts that are covering the firm, Marketbeat Ratings reports...
MarketBeat·29d ago
News Placeholder
SAB Biotherapeutics (NASDAQ:SABS) Coverage Initiated at Rodman & Renshaw
Rodman & Renshaw initiated coverage on SAB Biotherapeutics in a report on Thursday. They issued a "buy" rating and a $13.00 target price on the stock...
MarketBeat·1mo ago
News Placeholder
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Up 21.1% in March
SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) saw a large increase in short interest in March. As of March 13th, there was short interest totaling 1,953,472 shares, an increase of 21.1% from the February 26th total of 1,613,558 shares. Based on an average daily volume of 918,838...
MarketBeat·1mo ago
News Placeholder
SAB Biotherapeutics (SABS) to Release Earnings on Friday
SAB Biotherapeutics (NASDAQ:SABS) will be releasing its Q4 2025 earnings before the market opens on Friday, March 27. (View Earnings Report at...
MarketBeat·2mo ago
News Placeholder
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update
SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) was the target of a large decrease in short interest during the month of February. As of February 27th, there was short interest totaling...
MarketBeat·2mo ago
News Placeholder
Commodore Capital LP Takes Position in SAB Biotherapeutics, Inc. $SABS
Commodore Capital LP purchased a new position in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the...
MarketBeat·2mo ago
News Placeholder
SAB Biotherapeutics (NASDAQ:SABS) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen lowered SAB Biotherapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·2mo ago
<
1
2
...
>

Latest SABS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.